Peer-Reviewed Publication

J Prim Care Community Health2024;1521501319231223437.January 1, 2024Journal Article

A Real-World Precision Medicine Program Including the KidneyIntelX Test Effectively Changes Management Decisions and Outcomes for Patients With Early-Stage Diabetic Kidney Disease.

Joji Tokita¹, David Lam¹, Aida Vega¹, Stephanie Wang¹, Leonard Amoruso¹, Tamara Muller¹, Nidhi Naik¹, Shivani Rathi¹, Sharlene Martin¹, Azadeh Zabetian², Catherine Liu¹, Catherine Sinfield¹, Tony McNicholas², Fergus Fleming², Steven G Coca¹, Girish N Nadkarni¹, Roger Tun², Mike Kattan³, Michael J Donovan^1,2, Arshad K Rahim¹

¹Icahn School of Medicine at Mount Sinai, New York, NY, USA.

²Renalytix AI, Inc., New York, NY, USA.

³Cleveland Clinic, Cleveland, OH, USA.

PubMed PMC DOI PDF

Abstract

INTRODUCTION/OBJECTIVE: The KidneyIntelX is a multiplex, bioprognostic, immunoassay consisting of 3 plasma biomarkers and clinical variables that uses machine learning to predict a patient's risk for a progressive decline in kidney function over 5 years. We report the 1-year pre- and post-test clinical impact on care management, eGFR slope, and A1C along with engagement of population health clinic…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.